Cyclacel Pharmaceuticals Inc. buy dimontalban
Start price
18.08.22
/
60%
€2.29
Target price
18.08.23
€7.00
Performance (%)
-33.11%
End price
22.08.22
€1.53
Summary
This prediction ended on 22.08.22 with a price of €1.53. The BUY prediction by dimontalban for Cyclacel Pharmaceuticals Inc. performed very badly with a performance of -33.11%. dimontalban has 60% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Cyclacel Pharmaceuticals Inc. | - | - | - |
| iShares Core DAX® | 2.594% | -1.158% | 14.782% |
| iShares Nasdaq 100 | 3.553% | -1.727% | 43.265% |
| iShares Nikkei 225® | 0.687% | -8.354% | 18.454% |
| iShares S&P 500 | 2.209% | -0.942% | 31.361% |
According to dimontalban what are the pros and cons of Cyclacel Pharmaceuticals Inc. for the foreseeable future?
Pros
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Rising EBIT margin expected
EBIT growth >5% per year expected
Fair valuation
Good rating
High Investments for future growth
Very good company culture
Very capable Management
Leading role in innovation
Some uniques
Differentiated customer and product portfolio
Growths faster than the competition
Sustainability is important
Stable Large shareholder and/or long term investor
Top 10 in its market
Known brand
Very Future proof/growth oriented business model
Cons
Very low/no dividend yield expected
negative Cash Flow expected
High risks in the balance sheet
Increased challenges to pay loans and raise capital
ROE lower than 10% per year
High risks for its business
Significant cyclical dependencies